Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders.

Frontiers in Pharmacology
Francisco NavarreteJorge Manzanares

Abstract

Drug treatments available for the management of substance use disorders (SUD) present multiple limitations in efficacy, lack of approved treatments or alarming relapse rates. These facts hamper the clinical outcome and the quality of life of the patients supporting the importance to develop new pharmacological agents. Lately, several reports suggest that cannabidiol (CBD) presents beneficial effects relevant for the management of neurological disorders such as epilepsy, multiple sclerosis, Parkinson's, or Alzheimer's diseases. Furthermore, there is a large body of evidence pointing out that CBD improves cognition, neurogenesis and presents anxiolytic, antidepressant, antipsychotic, and neuroprotective effects suggesting potential usefulness for the treatment of neuropsychiatric diseases and SUD. Here we review preclinical and clinical reports regarding the effects of CBD on the regulation of the reinforcing, motivational and withdrawal-related effects of different drugs of abuse such as alcohol, opioids (morphine, heroin), cannabinoids, nicotine, and psychostimulants (cocaine, amphetamine). Furthermore, a special section of the review is focused on the neurobiological mechanisms that might be underlying the 'anti-addictive' act...Continue Reading

References

Mar 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·R SpanagelT S Shippenberg
Jan 1, 1991·Psychopharmacology·A W ZuardiJ M Cunha
Jan 1, 1990·Psychopharmacology·F S GuimarãesA W Zuardi
Jul 1, 1985·Pharmacology, Biochemistry, and Behavior·G B Chesher, D M Jackson
Dec 1, 1963·Tetrahedron·R Mechoulam, Y Shvo
Aug 1, 1981·Journal of Clinical Pharmacology·E A Carlini, J M Cunha
Jun 20, 2002·Life Sciences·Fred O Risinger, Janel M Boyce
Aug 17, 2002·Psychoneuroendocrinology·E PintoM Ansseau
Oct 16, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Margaret HaneyRichard W Foltin
Nov 5, 2003·Nature Reviews. Neuroscience·Daniele Piomelli
May 21, 2004·Nature Reviews. Neuroscience·Roy A Wise
Apr 21, 2005·European Journal of Pharmacology·Fabrício A Moreira, Francisco S Guimarães
May 10, 2005·The Journal of Pharmacology and Experimental Therapeutics·Carol HamelinkRobert L Eskay
Jul 30, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Leonora E LongDavid A Taylor
Nov 1, 2005·Neurochemical Research·Ethan B RussoKeith K Parker
Feb 18, 2006·Trends in Neurosciences·Rafael MaldonadoFernando Berrendero
Feb 21, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Markus KathmannEberhard Schlicker
Apr 7, 2006·Handbook of Experimental Pharmacology·K Mackie
Apr 14, 2006·Current Opinion in Psychiatry·Alan J Budney, John R Hughes
May 5, 2006·Proceedings of the National Academy of Sciences of the United States of America·Erica J CarrierCecilia J Hillard
Jun 14, 2006·Drug and Alcohol Dependence·Alan J BudneyBetsy Bahrenburg
Jun 20, 2006·Behavioural Brain Research·Leonardo B M ResstelFrancisco S Guimarães
Aug 1, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Fabrício A MoreiraFrancisco S Guimarães
Oct 25, 2006·Journal of Studies on Alcohol·Stephen A MaistoChristine M Davis
Feb 24, 2007·Progress in Neurobiology·Christian P MüllerMaria A De Souza Silva
Apr 3, 2007·European Archives of Psychiatry and Clinical Neuroscience·Juan J Canales
Sep 19, 2007·British Journal of Pharmacology·E RybergP J Greasley
Dec 28, 2007·Psychopharmacology·Margaret HaneyRichard W Foltin
Apr 2, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Celia J A Morgan, H Valerie Curran
Apr 17, 2008·British Journal of Pharmacology·M SolinasD Piomelli
Apr 22, 2008·The Cochrane Database of Systematic Reviews·R P MattickM Davoli
Jun 24, 2008·Journal of Substance Abuse Treatment·Ari P KirshenbaumWarren K Bickel
Sep 20, 2008·Journal of Psychopharmacology·A W ZuardiV Tumas
Dec 20, 2008·Journal of Neurochemistry·Sabah KelaïLaurence Lanfumey
Aug 28, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·George F Koob, Nora D Volkow
Nov 27, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Yanhua RenYasmin L Hurd

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.

Cannabis & Cognition

The effect of cannabis on cognitive functioning is being explored for short and long-term effects. Recent studies have shown conflicting results, with some showing no significant effects and others showing neuropsychological impairment. Discover the latest research on cannabis and cognition here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here